CN1210063C - Complex local medicine for mainly treating oral ulcer - Google Patents
Complex local medicine for mainly treating oral ulcer Download PDFInfo
- Publication number
- CN1210063C CN1210063C CN 03158380 CN03158380A CN1210063C CN 1210063 C CN1210063 C CN 1210063C CN 03158380 CN03158380 CN 03158380 CN 03158380 A CN03158380 A CN 03158380A CN 1210063 C CN1210063 C CN 1210063C
- Authority
- CN
- China
- Prior art keywords
- medicine
- oral ulcer
- effective active
- active composition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to compound local medicine mainly for treating oral ulcer, which is characterized in that a substrate carrier of the compound local medicine contains the following effective active components by weight percentage: 0.1 to 5% of antibacterial medicine, 0.05 to 5% of local anesthetic medicine and 0.01 to 0.5% of cortical hormone anti-inflammation medicine. The present invention has the advantages that various kinds of medicine are utilized to form a compound formula, and the present invention simultaneously focuses on a plurality of interactional pathogenetic factors and can simultaneously alleviate pain and inflammation and prevent secondary infection. Symptoms are eliminated rapidly, and effects are obvious.
Description
Technical field:
The present invention relates to a kind of local application for the treatment of oral ulcer, especially a kind of compound topical medicine that cures mainly oral ulcer.
Background technology:
Oral ulcer mainly betides positions such as oral mucosa, lip, tongue, cheek, palate, pharynx, gum, shows as the rotten face of mucosa, ulcer companion's inflammation and pain, hinder and take food and speak, but infected by microbes in the secondary oral cavity aggravates disease.At present, the therapeutic scheme of oral ulcer has two kinds of whole body therapeutic and topical therapeutics.In view of the cause of disease is not understood fully as yet at last, and self limiting and recurrent are arranged, oral ulcer are mainly adopted topical therapeutic,, reach relief of symptoms to play antiinflammatory, pain relieving and prevention infection effect targetedly, alleviate speak, the misery during feed.Because the existing medicine that is used for topical therapeutic exists medicine and drug effect single, generally can not carry out many-side processing by pathology and clinical manifestation, thereby remission is incomplete only at pain or inflammation or infect in a certain respect, curative effect is undesirable.
Summary of the invention:
The objective of the invention is to:, provide a kind of compound topical medicine of new treatment oral ulcer at the problem that exists in the conventional treatments of treatment oral ulcer.
The object of the present invention is achieved like this: a kind of compound topical medicine that cures mainly oral ulcer, it is characterized in that: contain following effective active composition (percentage by weight) in the medium carrier of compound topical with medicine: antibacterials 0.1～5%, local anesthetic 0.05～5%, 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs 0.01～0.5%, described antibacterials are Chlorhexidine Diacetate, or bromo geramine, or chlortetracycline, or tetracycline, or metronidazole, or tinidazole, or secnidazole, or domiphen bromide, described local anesthetic is a tetracaine hydrochloride, or lidocaine hydrochloride, or dyclonine hydrochloride, described 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs is a dexamethasone acetate, or omcilon, or the 17-clobetasone butyrate, or 17-butanoic acid hydrocortisone, or dexamethasone sodium phosphate, or 21-Flumetasoni Pivalate.
Antibacterials in the effective active composition that contains in the described medium carrier and content thereof are Chlorhexidine Diacetate 0.1～2%, or bromo geramine 0.5%, or chlortetracycline 0.1～1%, or tetracycline 0.1～1%, or metronidazole 0.5～5%, or tinidazole 0.5～5%, or secnidazole 0.5～5%, or domiphen bromide 0.1～2%.
Local anesthetic in the effective active composition that contains in the described medium carrier and content thereof are tetracaine hydrochloride 0.05～2%, or lidocaine hydrochloride 0.05～5%, or dyclonine hydrochloride 0.05～2%.
17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs in the effective active composition that contains in the described medium carrier and content thereof are dexamethasone acetate 0.03～0.5%, or omcilon 0.05～0.2%, or 17-clobetasone butyrate 0.01～0.1%, or 17-butanoic acid hydrocortisone 0.05～0.2%, or dexamethasone sodium phosphate 0.03～0.5%, or 21-Flumetasoni Pivalate 0.01～0.1%.
The effective active composition that described compound external-use medicine contains forms membrane or liniment or unguentum with after medium carrier mixes.
It was once on probation clinically as inner preparation to use Chlorhexidine Diacetate, tetracaine hydrochloride and dexamethasone acetate, major advantage is can be simultaneously at pain, inflammation and prevent secondary infection, and symptom is eliminated fast, effect is obviously with comprehensive, excipient can dissolve about 20 minutes, disappeared, and drug effect can be kept 0.5～1 hour (is index to relieve the pain), can use on the feed or before talking, very convenient, user does not have discomfort, and practicality also obviously is better than the existing medicine that is used for topical therapeutic.
This shows, the invention has the advantages that: utilize multiple medicine to form compound recipe, at a plurality of interactional morbidity link of oral ulcer, make treatment more targeted simultaneously, act on extensivelyr, darker, reach better therapeutic purposes.
The specific embodiment:
Below the nonrestrictive part embodiment that the present invention relates to that exemplified.
Embodiment 1:
Antibacterials adopt Chlorhexidine Diacetate 0.5% in the effective active composition of present embodiment, local anesthetic adopts tetracaine hydrochloride 1%, the 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs adopts dexamethasone acetate 0.05%, and medium carrier adopts ethanol, glycerol, film former and distilled water.
Embodiment 2:
Antibacterials adopt bromo geramine 0.5% in the effective active composition of present embodiment, and local anesthetic adopts lidocaine hydrochloride 1%, and the 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs adopts omcilon 0.1%, and medium carrier adopts ethanol, glycerol, film former and distilled water.
Embodiment 3:
Antibacterials adopt chlortetracycline 1% in the effective active composition of present embodiment, and local anesthetic adopts dyclonine hydrochloride 1%, and the 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs adopts 17-butanoic acid chlorine to believe his pine 0.1%, and medium carrier adopts ethanol, glycerol, film former and distilled water.
Embodiment 4
Earlier three kinds of effective active compositions among embodiment 1 or embodiment 2 or the embodiment 3 are dissolved in the ethanol of total amount 5～10% or the distilled water stand-by respectively; With an amount of distilled water film former is swelled into the glycerol mixing that gluey back adds total amount 1～3%; The solution that is dissolved with the effective active composition added be mixed with in the jelly of glycerol, stir back bed board, drying, skinning, cut apart the formation membrane, the gross area of membrane is 1000cm
2
Embodiment 5:
Antibacterials adopt tetracycline 1% in the effective active composition of present embodiment, local anesthetic adopts lidocaine hydrochloride 2%, the 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs adopts 17-butanoic acid hydrocortisone 0.1%, and medium carrier adopts solubilizing agent, glycerol, film former and distilled water.
Embodiment 6:
Antibacterials adopt metronidazole 2% in the effective active composition of present embodiment, local anesthetic adopts lidocaine hydrochloride 1%, the 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs adopts dexamethasone sodium phosphate 0.05%, and medium carrier adopts solubilizing agent, glycerol, film former and distilled water.
Embodiment 7:
Antibacterials adopt tinidazole 1% in the effective active composition of present embodiment, local anesthetic adopts dyclonine hydrochloride 1%, the 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs adopts 21-Flumetasoni Pivalate 0.05%, and medium carrier adopts solubilizing agent, glycerol, film former and distilled water.
Embodiment 8:
Earlier three kinds of effective active compositions among embodiment 5 or embodiment 6 or the embodiment 7 are dissolved in the solubilizing agent; With an amount of distilled water film former is swelled into the glycerol mixing that gluey back adds total amount 5～30%, to be dissolved with the solubilizing agent of two kinds of effective active compositions adds in the swollen jelly, add the gross weight of an amount of distilled water until pharmaceutical preparation again, the formation liniment stirs.
Embodiment 9:
Antibacterials adopt secnidazole 2% in the effective active composition of present embodiment, local anesthetic adopts lidocaine hydrochloride 1%, the 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs adopts dexamethasone acetate 0.05%, and medium carrier adopts hexadecanol, vaseline, liquid paraffin, glyceryl monostearate, solubilizing agent, emulsifying agent, ethyl hydroxybenzoate and distilled water.
Embodiment 10:
Antibacterials adopt domiphen bromide 0.5% in the effective active composition of present embodiment, local anesthetic adopts tetracaine hydrochloride 1%, the 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs adopts omcilon 0.1%, and medium carrier adopts hexadecanol, vaseline, liquid paraffin, glyceryl monostearate, solubilizing agent, emulsifying agent, ethyl hydroxybenzoate and distilled water.
Embodiment 11:
Earlier the ethyl hydroxybenzoate with three kinds of effective active compositions among embodiment 9 or the embodiment 10 and total amount 0.1% is dissolved in the solubilizing agent; Again the hexadecanol of total amount 8～12%, the vaseline of total amount 5～10%, the liquid paraffin of total amount 8～12%, the monostearate and an amount of emulsifier of total amount 5～10% are heated to 80～85 ℃; The glyceride of total amount 0.5～5% and an amount of distilled water are mixed and heated to 80～85 ℃, and with the mixture mixing and emulsifying of itself and above-mentioned hexadecanol, vaseline, liquid paraffin, monostearate and emulsifying agent; Mixture after the emulsifying is left thermal source, stir when being cooled to 65 ℃, add the solubilizing agent that is dissolved with two kinds of effective active compositions and ethyl hydroxybenzoate, the formation emulsifiable paste stirs.
Claims (5)
1, a kind of compound topical medicine that cures mainly oral ulcer, it is characterized in that: contain following effective active composition (percentage by weight) in the medium carrier of compound topical with medicine: antibacterials 0.1～5%, local anesthetic 0.05～5%, 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs 0.01～0.5%, described antibacterials are Chlorhexidine Diacetate, or bromo geramine, or chlortetracycline, or tetracycline, or metronidazole, or tinidazole, or secnidazole, or domiphen bromide, described local anesthetic is a tetracaine hydrochloride, or lidocaine hydrochloride, or dyclonine hydrochloride, described 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs is a dexamethasone acetate, or omcilon, or the 17-clobetasone butyrate, or 17-butanoic acid hydrocortisone, or dexamethasone sodium phosphate, or 21-Flumetasoni Pivalate.
2, the compound topical medicine that cures mainly oral ulcer according to claim 1, it is characterized in that: antibacterials in the effective active composition that contains in the described medium carrier and content thereof are Chlorhexidine Diacetate 0.1～2%, or bromo geramine 0.5%, or chlortetracycline 0.1～1%, or tetracycline 0.1～1%, or metronidazole 0.5～5%, or tinidazole 0.5～5%, or secnidazole 0.5～5%, or domiphen bromide 0.1～2%.
3, the compound topical medicine that cures mainly oral ulcer according to claim 1, it is characterized in that: local anesthetic in the effective active composition that contains in the described medium carrier and content thereof are tetracaine hydrochloride 0.05～2%, or lidocaine hydrochloride 0.05～5%, or dyclonine hydrochloride 0.05～2%.
4, the compound topical medicine that cures mainly oral ulcer according to claim 1, it is characterized in that: 17-hydroxy-11-dehydrocorticosterone anti-inflammation drugs in the effective active composition that contains in the described medium carrier and content thereof are dexamethasone acetate 0.03～0.5%, or omcilon 0.05～0.2%, or 17-clobetasone butyrate 0.01～0.1%, or 17-butanoic acid hydrocortisone 0.05～0.2%, or dexamethasone sodium phosphate 0.03～0.5%, or 21-Flumetasoni Pivalate 0.01～0.1%.
5, the compound topical medicine that cures mainly oral ulcer according to claim 1 is characterized in that: the effective active composition that described compound external-use medicine contains forms membrane or liniment or unguentum with after medium carrier mixes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03158380 CN1210063C (en) | 2003-09-29 | 2003-09-29 | Complex local medicine for mainly treating oral ulcer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03158380 CN1210063C (en) | 2003-09-29 | 2003-09-29 | Complex local medicine for mainly treating oral ulcer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1528460A CN1528460A (en) | 2004-09-15 |
| CN1210063C true CN1210063C (en) | 2005-07-13 |
Family
ID=34287282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03158380 Expired - Fee Related CN1210063C (en) | 2003-09-29 | 2003-09-29 | Complex local medicine for mainly treating oral ulcer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1210063C (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101396370B (en) * | 2007-09-27 | 2011-06-01 | 北京人福军威医药技术开发有限公司 | Medicine composition for treating mouth, throat disease and preparation method thereof |
| BR112012029697A2 (en) * | 2010-05-24 | 2016-08-02 | Indena Spa | tamarind seed polysaccharide for use in the treatment of inflammatory diseases |
| CN102579702B (en) * | 2012-03-14 | 2015-07-08 | 山东赛克赛斯药业科技有限公司 | Medicine for treating dental ulcer and preparation method thereof |
| CN102935088A (en) * | 2012-10-25 | 2013-02-20 | 祁建春 | Injection therapy and drug constitutes for curing recurrent aphthous ulcer |
| CN103494827B (en) * | 2013-10-23 | 2014-12-03 | 武汉武药科技有限公司 | Compound buccal adhesive tablet containing triamcinolone acetonide and preparation method thereof |
| CN103919786A (en) * | 2014-05-06 | 2014-07-16 | 青岛市市立医院 | Dental medicinal membrane and preparation method thereof |
| CN103977012A (en) * | 2014-05-06 | 2014-08-13 | 青岛市市立医院 | Drops for treating oral ulcer and preparation method thereof |
| CN104490920A (en) * | 2014-11-28 | 2015-04-08 | 青岛市市立医院 | Paste film for treating oral ulcer and preparation method thereof |
| CN105477002A (en) * | 2016-01-10 | 2016-04-13 | 张庆峰 | Preparation method of secnidazole and dexamethasone oral sustained-release medicine membrane |
| CN111388500B (en) * | 2020-05-22 | 2021-08-24 | 陕西恒远生物科技有限公司 | Pharmaceutical composition for oral mucosa ulcer inflammatory pain and bacteriostasis, gel and preparation method thereof |
| CN115025125B (en) * | 2022-06-24 | 2023-09-29 | 四川大学 | Pharmaceutical composition for treating dental ulcer and preparation method thereof |
-
2003
- 2003-09-29 CN CN 03158380 patent/CN1210063C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1528460A (en) | 2004-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5324746A (en) | Method of treating damaged mucosal and epithelial tissues with misoprostol | |
| US5977087A (en) | Topical preparation for treatment of aphthous ulcers and other lesions | |
| CN1210063C (en) | Complex local medicine for mainly treating oral ulcer | |
| US4555524A (en) | Transdermal 2-(4-isobutylphenyl)-propionic acid medication and methods | |
| KR102165993B1 (en) | Injection composition for Local Fat-Dissolving | |
| RU2290918C1 (en) | Means and method for treating inflammatory diseases of mucous membrane in oral cavity | |
| CN1169561C (en) | Medicine for treating diseases of rectum and anus | |
| US5886047A (en) | Topical pharmaceutical preparation for fever blisters and other viral infections and method of use | |
| ZA200601054B (en) | Method and composition for treating burned skin | |
| CN1692940A (en) | External-applied ointment used for treating thyropathy, and its prepn. method | |
| US5294440A (en) | Composition for treatment of cold sores | |
| RU2058783C1 (en) | Agent for mouth mucosa treatment | |
| CN1546094A (en) | Exterior coating medicine for relieving toothache | |
| CN111317716A (en) | Vitamin K1The colitis hemostatic repair emulsion | |
| CN116059383B (en) | Flurbiprofen salt gel and crystallization inhibitor thereof | |
| RU2789515C1 (en) | Pharmaceutical composition based on aqua-complex of titanium glycerosolvate in combination with l-arginine for treatment of inflammatory diseases of oral mucosa | |
| RU2549445C1 (en) | Method of treating periodontitis and oral mucosal diseases associated with helicobacter infection, and method for using it | |
| US11642328B2 (en) | Creatine, its derivatives, compositions and methods of use thereof | |
| CN113262216A (en) | External preparation for eliminating skin surface red swelling and easing pain | |
| CN1939469A (en) | Chinese medicinal plaster with analgetic, hemostatic, repercussive and sarcogenic functions | |
| CN111329881A (en) | Oral ulcer film and preparation method and application thereof | |
| RU2137461C1 (en) | Composition for treatment of mouth cavity sicknesses | |
| CN114668721A (en) | External medicine for treating oral diseases and preparation method thereof | |
| CN118161547A (en) | Traditional Chinese medicine formula for treating acne | |
| CN113332234A (en) | Formula of tranilast emulsifiable paste and preparation process thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050713 Termination date: 20091029 |